10-Q · May 11, 2026
Skye Bioscience reported no revenues for Q1 2026, continuing the trend from previous periods. The EPS loss narrowed to -0.32 from -0.36 in the prior quarter but remains negative, indicating ongoing challenges in…
Earnings analysis · 10-Q
SKYE earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q extract does not include the quarterly income statement, balance sheet, or cash-flow amounts, so revenue, margins, EPS, cash flow, and segment trends cannot be quantified from the provided filing text.…
Read full summary
The supplied 10-Q extract does not include the quarterly income statement, balance sheet, or cash-flow amounts, so revenue, margins, EPS, cash flow, and segment trends cannot be quantified from the provided filing text. The main development is the proposed Redx transaction, alongside restored Nasdaq equity compliance effective June 23, 2026, but Skye remains exposed to a $1.00 minimum-bid-price deadline of September 14, 2026 and significant transaction execution and dilution risks. The company’s reported staffing level of only two full-time employees further heightens execution and reporting risk.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Nasdaq Equity Compliance Restored
Nasdaq approved Skye’s transfer from the Nasdaq Global Market to the Nasdaq Capital Market, effective June 23, 2026, resolving the stated $10.0 million stockholders’ equity deficiency.
-
Proposed Transaction Includes Financing
The proposed Redx transaction contemplates approximately $67.9 million of gross Concurrent Financing and $36.0 million of gross Series A Financing, subject to the stated assumptions.
-
Disclosure Controls Deemed Effective
The filing reports that Skye’s CEO and CFO concluded its disclosure controls were effective at a reasonable assurance level as of June 30, 2026.
-
Transaction Ownership Structure Disclosed
The proposed transaction would result in current Skye pre-transaction equityholders owning approximately 5.38% of the combined company, versus 46.17% for Redx pre-transaction equityholders and 48.45% for financing investors.
What to watch
-
Nasdaq Minimum-Bid-Price Deficiency
Skye received a Nasdaq notice after its closing bid price remained below the $1.00 minimum for 30 consecutive business days. The company has until September 14, 2026 to regain compliance, subject to potential extension and Nasdaq requirements.
-
Redx Transaction Closing Risk
Completion of the proposed Redx transaction is uncertain because required closing conditions may not be satisfied or waived. Failure or delay could lead to transaction costs, potential termination fees, litigation, and a decline in the stock price.
-
Dependence on Two Employees
As of the filing date, Skye had only two full-time employees. The loss of one or more remaining employees could impair transaction execution, day-to-day operations, and public-company reporting obligations.
-
Substantial Transaction Dilution
Current Skye stockholders are expected to own approximately 5.38% of the combined company after the transaction, creating substantial dilution if the combined company does not realize the anticipated strategic and financial benefits.
-
Potential $5 Million MVLS Standard
Nasdaq’s proposed $5 million Market Value of Listed Securities requirement was automatically stayed on July 29, 2026, but the filing states there is no assurance that Skye’s MVLS will remain at or above $5 million if the rule becomes effective.
-
Liquidation Risk if Deal Fails
If the Redx transaction or another strategic transaction is not completed, the board may pursue dissolution and liquidation. The filing states that stockholders could lose all or a significant portion of their investment after obligations and contingent liabilities are reserved.
Management's outlook
No quantitative revenue or EPS guidance was provided in the supplied 10-Q extract. The filing focuses on the proposed Redx transaction, liquidity/listing risks, and transaction-related contingencies.
Earlier filings 4
10-K · March 10, 2026
Skye Bioscience (SKYE) reported significant operating losses exceeding $55 million in 2025, attributed primarily to escalating R&D costs for its lead candidate nimacimab. The company's liquidity remains a concern, with…
10-Q · November 10, 2025
Skye Bioscience reported no revenue for Q3 2025, consistent with previous quarters, while maintaining negative EPS of -0.32, which aligns with consensus estimates. Research and development expenses surged to $9.36…
10-Q · August 7, 2025
Skye Bioscience reported no revenue in Q2 2025, with EPS of -$0.44 missing consensus estimates by $0.12. R&D expenses surged 252% year-over-year to $14.34 million, primarily driven by activities related to the nimacimab…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.